A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Sankar, Srividya
- Game Changer in the Management of Diabetic Neuropathy: an Indian Perspective - Post-Marketing Surveillance of Epalrestat and Methylcobalamin
Authors
1 Scientific Department, Aristo Pharmaceuticals Private Limited, Mumbai, IN
Source
The Indian Practitioner, Vol 66, No 12 (2013), Pagination: 745-750Abstract
Background: Diabetic Neuropathy is one amongst the most common long - term complication of diabetes. It is prevalent in more than 50% of people suffering from diabetes mellitus. Management of diabetic neuropathy is aimed at targeting the pathogenetic factors that leads to neuropathy. Epalrestat helps to prevent neuronal degeneration by reducing the accumulation of toxic sorbitol and decreasing the oxidative stress while methylcobalamin helps to recover neuronal injury.The purpose of this study was to evaluate safety and efficacy of fixed dose combination of Epalrestat+ Methylcobalamin in patients with diabetic neuropathy.Method: A prospective, open-label, non-comparative study was conducted in different regions of India. A pool of 150 patients was involved in the study and the duration of study was 12 weeks. A fixed dose combination of Epalrestat 50 mg + Methylcobalamin 500 mcg three times a day was administered.
Results: At the end of the study, a significant difference was observed in various parameters from baseline. A significant reduction in neuropathic symptoms was observed at the end of the treatment (58% reduction at 4th week and 94% reduction at 12th week). The mean pain intensity score reduced to 89.4% from baseline. A positive effect was also observed in muscle strength that increased to 36% in patients. As per investigator's assessment about efficacy and tolerability, 82.7% of patients reported excellent efficacy and 86.7% of patients reported excellent tolerability. The therapy was well tolerated with few adverse events (AEs).
Conclusion: The results of this study confirm that this combination of Epalrestat+ Methylcobalamin is well tolerated and it showed significant improvement in the symptoms of diabetic neuropathy at the end of treatment.
Keywords
Diabetes Neuropathy, Epalrestat, Methylcobalamin, Polyol Pathway, Aldose Reductase Inhibitor, Diabetes.- A Review of the Role of Silodosin as Medical Expulsive Therapy for Ureteral Stones
Authors
1 Aristo Pharmaceuticals Private Limited, Mumbai, IN
Source
The Indian Practitioner, Vol 73, No 9 (2020), Pagination: 25-32Abstract
Urolithiasis is a chronic human condition that has immense public health importance and it poses a tremendous economic burden on our society. Medical expulsive therapy (MET) for the treatment of ureteral stones has emerged as a cost-effective approach. In the last few years, a number of drugs have been introduced and used successfully as MET for the expulsion of small, uncomplicated ureteral calculi. Using a selective α-adrenoceptor blocker for MET has emerged as an effective treatment approach and is widely used for ureteral stones. Silodosin, a selective α-blocker, has a higher selectivity for the α1A receptor as compared to other agents in the class. The objective of this review is to determine the efficacy and safety of Silodosin in MET as compared to placebo and Tamsulosin.Keywords
Ureteral Stone Expulsion, Urolithiasis, alpha-1 adrenoceptor blocker, Silodosin, Tamsulosin.References
- Yang D, Wu J, Yuan H, Cui Y. The efficacy and safety of silodosin for the treatment of ureteral stones: a systematic review and meta-analysis. BMC Urol. 2016;16 (23):1-8.
- Huang W, Xue p, Zong H, Zhang Y. Efficacy and safety of silodosin in the medical expulsion therapy for distal ureteral calculi: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016 Jan;81(1):13-22.
- Liu Y, Chen Y, Liao B, Luo D, Wang K, Li H, Zeng G. Epidemiology of urolithiasis in Asia. Asian J Urol. 2018;5:205 - 14.
- Kumar S, Kumar J, Agrawal MM, Singh SK, Agrawal S, Parmar KM. Role of tamsulosin, tadalafil, and silodosin as the medical expulsive therapy in lower ureteric stone: a randomized trial (a pilot study). Urology 2015;85(1):59-63.
- Gupta S, Lodh B, Singh AK, Somarendra K, Meitei KS, Singh SR. Comparing the efficacy of tamsulosin and silodosin in the medical expulsion therapy for ureteral calculi. J Clin Diagn Res. 2013 Aug;7(8):1672-74.
- Campschroer T, Zhu X, Vernooij RWM, Lock MTWT. Alphablockers as medical expulsive therapy for ureteral stones. Cochrane Database Syst Rev. 2018 Apr 5;4(4):CD008509.
- Dell’Atti L. Silodosin versus tamsulosin as medical expulsive therapy for distal ureteral stones: a prospective randomized study. Urologia 2015;82(1):54-57.
- Bos D, Kapoor A. Update on medical expulsive therapy for distal ureteral stones: beyond alpha-blockers. Can Urol Assoc J 2014;8(11-12):442-5.
- Lipkin M, Shah O. The use of alpha-blockers for the treatment of nephrolithiasis. Rev Urol. 2006;8(suppl 4):35-42
- Malin JM, Deane RF, Boyarsky S. Characterisation of adrenergic receptors in human ureter. Br J Urol. 1970;42:171-174.
- Hanno PM, Wein AJ, Malkowicz B. Penn Clinical Manual of Urology. 1st ed. Philadelphia: Saunders – Elsevier; 2007. 507p.
- Sigala S, Dellabella M, Milanese G, Fornari S, Faccoli S, Palazzolo F, Peroni A, Mirabella G, Cunico SC, Spano P, Muzzonigro G. Evidence for the presence of alpha1 adrenoceptor subtypes in the human ureter. Neurourol Urodyn. 2005;24(2):142-8.
- Itoh Y, Kojima Y, Yasui T, Tozawa K, Sasaki S, Kohri K. Examination of alpha 1 adrenoceptor subtypes in the human ureter. Int J Urol. 2007;14: 749–53.
- Tomiyama Y, Kobayashi K, Tadachi M, Kobayashi S, Inada Y, Kobayashi M, Yamazaki Y. Expressions and mechanical functions of alpha1- adrenoceptor subtypes in hamster ureter. Eur J Pharmacol. 2007 Nov 14;573(1-3):201-5.
- Bagot K, Chess-Williams R. Alpha(1A/L)-adrenoceptors mediate contraction of the circular smooth muscle of the pig urethra. Auton Autacoid Pharmacol. 2006 Oct;26(4):345-53.
- Sasaki S, Tomiyama Y, Kobayashi S, Kojima Y, Kubota Y, Kohri K. Characterization of α1-adrenoceptor subtypes mediating contraction in human isolated ureters. Urology. 2011 Mar;77(3):762.e13-7.
- McCune DF, Edelmann SE, Olges JR, Post GR, Waldrop BA, Waugh DJJ, Perez DM, Piascik MT. Regulation of the cellular localization and signaling properties of the α1B - and α1A -adrenoceptors by agonists and inverse agonists. Mol Pharmacol. 2000 Apr; 57(4): 659-66.
- Chalothorn D, McCune DF, Edelmann SE, García-Cazarín ML, Tsujimoto G, Piascik MT. Differences in the cellular localization and agonist- mediated internalization properties of the alpha(1)-adrenoceptor subtypes. Mol Pharmacol. 2002 May;61(5):1008-16.
- Tsuzaka Y, Matsushima H, Kaneko T, Yamaguchi T, Homma Y. Naftopidil vs silodosin in medical expulsive therapy for ureteral stones: a randomized controlled study in Japanese male patients. Int J Urol. 2011; 18: 792–95.
- Sridharan K, Sivaramakrishnan G. Medical expulsive therapy in urolithiasis: a mixed treatment comparison network meta-analysis of randomized controlled clinical trials. Expert Opin Pharmacother. 2017 Oct;18(14):1421-31.
- Cervenàkov I, J Fillo J, Mardiak J, Kopecný M, Smirala J, Lepies P. Speedy elimination of ureterolithiasis in lower part of ureters with the alpha 1-blocker -tamsulosin. Int J Nephrol Urol. 2002; 34: 25–29.
- Dellabella M, Milanese G, Muzzonigro G. Efficacy of tamsulosin in the medical management of juxtavesical ureteral stones. J Urol. 2003;170:2202–5.
- Resim S, Ekerbicer H, Ciftci A. Effect of tamsulosin on the number and intensity of ureteral colic in patients with lower ureteral calculus. Int J Urol. 2005; 12:615–20.
- Sio MD, Autorino R, Lorenzo GD, Damiano R, Giordano D, Cosentino L, Pane U, Giacomo FD, Mordente S, D’Armiento M. Medical expulsive treatment of distal- ureteral stones using tamsulosin: a single-center experience. J Endourol. 2006 Jan;20(1):12-6.
- Yilmaz E, Batislam E, Basar MM, Tuglu D, Ferhat M, Basar H. The comparison and efficacy of 3 different alpha1- adrenergic blockers for distal ureteral stones. J Urol. 2005 Jun;173(6):2010-2.
- Porpiglia F, Ghignone G, Fiori C, Fontana D, Scarpa RM. Nifedipine versus tamsulosin for the Management of Lower Ureteral Stones. J Urol. 2004 Aug;172(2):568-71.
- Dellabella M, Milanese G, Muzzonigro G. Randomized trial of the efficacy of tamsulosin, nifedipine and phloroglucinol in medical expulsive therapy for distal ureteral calculi. J Urol. 2005 Jul;174(1):167-72.
- Itoh Y, Okada A, Yasui T, Hamamoto S, Hirose M, Kojima Y, Tozawa K, Sasaki S, Kohri K. Efficacy of selective α1A adrenoceptor antagonist silodosin in the medical expulsive therapy for ureteral stones. Int J Urol. 2011;18:672–74.
- Sur RL, Shore N, L’Esperance J, Knudsen B, Gupta M, Olsen S, Shah O. Silodosin to facilitate passage of ureteral stones: a multi-institutional, randomized, double-blinded, placebocontrolled trial. Eur Urol . 2015 May;67(5):959-64.
- Keating GM. Silodosin: A review of its use in the treatment of the signs and symptoms of benign prostatic hyperplasia. Drugs.2015;75:207–17.
- Tatemichi S, Kobayashi K, Maezawa A, Kobayashi M, Yamazaki Y, Shibata N. α1- adrenoceptor subtype selectivity and organ specificity of silodosin (KMD-3213). Yakugaku Zasshi. 2006 Mar;126:209-16.
- Martin DJ. Preclinical pharmacology of α1-adrenoceptor antagonists. Eur Urol 1999;36(suppl 1):35–41.
- Elgalaly H, Sakr A, Fawzi A, Salem EA, Desoky E, Shahin A, Kamel M. Silodosin vs tamsulosin in the management of distal ureteric stones: A prospective randomised study. Arab J Urol. 2016; 14: 12–17.
- Imperatore V, Fusco F, Creta M, Meo SD, Buonopane R, Longo N, Imbimbo C, Mirone V. Medical expulsive therapy for distal ureteric stones: tamsulosin versus silodosin. Arch Ital Urol Androl. 2014 Jun 30;86(2):103-7.
- Itoh Y, Okada A, Yasui T, Ando R, Tozawa K, Sasaki S, Kohri K. Administration of the selective alpha 1A-adrenoceptor antagonist silodosin facilitates expulsion of size 5–10 mm distal ureteral stones, as compared to control. Int Urol Nephrol.2013; 45:675–78.
- Gharib T, Mohey A, Fathi A, Alhefnawy M, Alazaby H, Eldakhakhny A. Comparative study between silodosin and tamsulosin in expectant therapy of distal ureteral stones. Urol Int. 2018;101(2):161-66.
- Wang CJ, Tsai P, Chang CH. Efficacy of silodosin in expulsive therapy for distal ureteral stones: a randomized doubleblinded controlled trial. Urol J. 2016 Jun 28;13(3):2666-71.
- Hsu YP, Hsu CW, Bai CH, Cheng SW, Chen KC, Chen C. Silodosin versus tamsulosin for medical expulsive treatment of ureteral stones: A systematic review and meta-analysis. PLoS One. 2018 Aug 28;13(8):1-24.
- The Journey of Vildagliptin: From Bench to Bedside
Authors
1 President – Medical & Regulatory Affairs, IN
2 Sr. General Manager – Scientific, Scientific Department, IN
3 Dy. Manager – Scientific, Scientific Department, Aristo Pharmaceuticals Private Limited, Mumbai, IN
Source
The Indian Practitioner, Vol 75, No 4 (2022), Pagination: 28-36Abstract
Vildagliptin, a DPP-4 inhibitor has been available for the management of type 2 diabetes mellitus for more than a decade. The extensive clinical data support from several vildagliptin clinical trials and real-world studies provided the clinicians with an effective treatment option for lowering blood glucose, which neither causes weight gain nor increased the risk of hypoglycemia and cardiovascular events. This article reviews the development journey of vildagliptin from the proof-of-concept of DPP-4 inhibition from its earlystages in the 1990s to the present, being an extensively studied, well-established DPP-4 inhibitor.The article highlights the clinical effectiveness, safety, and tolerability studies of vildagliptin, which proved vildagliptin as an effective and safe option in the armamentarium of type 2 diabetes mellitus management in this era of evidence-based medical practice. This vildagliptin journey, from proof-of-concept to a very well-established molecule gives a lesson that a novel concept takes time and requires focused efforts, persistence, and long-term perseverance for bringing it into clinical practice.
Keywords
Vildagliptin, gliptins, DPP-4 inhibitor, diabetes, glucose lowering therapyReferences
- Ahrén B. DPP-4 inhibition and the path to clinical proof.Front Endocrinol (Lausanne). 2019;10:376.
- Mathieu C, Kozlovski P, Paldánius PM, et al. Clinical safety and tolerability of vildagliptin - insights from randomised trials, observational studies and post-marketing surveillance. Eur Endocrinol. 2017;13(2):68-72.
- Foley JE. Insights Into GLP-1 and GIP Actions Emerging From Vildagliptin Mechanism Studies in Man. Front Endocrinol (Lausanne). 2019;10:780.
- Foley JE, Ahrén B. The vildagliptin experience - 25 years since the initiation of the novartis glucagon-like peptide-1 based therapy programme and 10 years since the first vildagliptin registration. Eur Endocrinol. 2017;13(2):56-61.
- Ahrén B, Simonsson E, Larsson H, et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care. 2002;25(5):869875.
- Winzelll M, Ahrén B. The high-fat diet–fed mouse: A model for studying mechanisms and treatment of impaired glucose tolerance and Type 2 Diabetes. Diabetes. 2004;53 Suppl 3:S215-9.
- BAhrén, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes. J Clin Endocrinol Metab.2004;89(5):2078-2084.
- Ahrén B, Gomis R, Standl E, Mills D, Schweizer A. Twelveand 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care. 2004;27(12):2874-2880.
- Ahren B, Pacini G, Foley JE, Schweizer A. Improved mealrelated β-Cell functionand insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1year. Diabetes Care.2005;28(8):1936-1940.
- Committee for Medicinal Products for Human Use.European Medicines Agency- CHMP Assessment Report (Vildagliptin). 2012 September; 20.
- Iftekar M, Kalaiselvan V, Gyanendra NS. Efficacy and safety of Vildagliptin in the management of type 2 Diabetes Mellitus. Indian J Pharm Pract. 2012;5(4):8-15.
- Prato SD. Ten years of Vildagliptin. Eur Endocrinol.2017;13(2):54-55.
- Mohan V, Zargar A, Chawla M, et al. Efficacy of a combination of metformin and vildagliptin in comparison to metformin alone in type 2 diabetes mellitus: A multicentre, retrospective, real-world evidence study. Diabetes, Metab Syndr Obes Targets Ther. 2021;14:2925-2933.
- Keating GM. Vildagliptin: a review of its use in Type 2 Diabetes Mellitus. Drugs. 2014;74(5):587-610.
- Garber AJ, Foley JE, Banerji MA, et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes, Obes Metab. 2008;10(11):1047-1056.
- Rosenstock J, Baron MA, Camisasca RP, Cressier F, Couturier A, Dejager S. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.Diabetes, Obes Metab. 2007;9(2):175-185.
- Kikuchi M, Haneda M, Koya D, et al. Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus. Diabetes Res Clin Pract.2010;89(3):216-223.
- Lukashevich V, Prato SD, Araga M, Kothny W. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea. Diabetes, Obes Metab. 2014;16(5):403-409.
- Derosa G, Maffioli P, Ferrari I, et al. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride inpoorly controlled type 2 diabetic patients. Horm Metab Res.2010;42(9):663-669.
- Lukashevich V, Schweizer A, Shao Q, Groop PH, Kothny W. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: A prospective 24-week randomized placebo-controlled trial. Diabetes, Obes Metab. 2011;13(10):947-954.
- Schweizer A, Dejager S, Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: A 24-week, double-blind, randomized trial.Diabetes, Obes Metab. 2009;11(8):804-812.
- Strain WD, Lukashevich V, Kothny W, Hoellinger MJ, Paldánius PM. Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): A 24 week, randomised, doubleblind, placebo-controlled study. Lancet. 2013;382(9890):409-416.
- Mcmurray JJV, Ponikowski P, Bolli GB, et al. effects of vildagliptin on ventricular function in patients with Type 2 Diabetes Mellitus and Heart Failure. A randomized placebo-controlled trial. J Am Coll Cardiol Hear Fail. 2018;6(1):8-17.
- Mathieu C, Barnett AH, Brath H, Conget I, Castro JJ De. Effectiveness and tolerability of second-line therapy with vildagliptin vs . other oral agents in type 2 diabetes : A reallife worldwide observational study (EDGE). Int J Clin Pract. 2013;67(10):947-956.
- Rosales R, Jaoude EA, M Al-Arouj, A Fawwad, A Orabi, P Shah, S DiTommaso, J Vaz ZAL. Clinical effectiveness and safety of vildagliptin in > 19,000 patients with type 2 diabetes : the GUARD study. Diabetes, Obes Metab. 2015;17(6):603- 607.
- Matthias Blüher, Ira Kurz, Simone Dannenmaier MD. Efficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study. World J Diabetes. 2012;3(9):161-169.
- Al-Arouj M, Hassoun AAK, Medlej R, et al. The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: The VIRTUE study. Int J Clin Pract. 2013;67(10):957-963.
- Halimi S, Levy M, Huet D, Quéré S, Dejager S. Experience with vildagliptin in type 2 diabetic patients fasting during Ramadan in France: Insights from the VERDI study. Diabetes Ther. 2013;4(2):385-398.
- Hassanein M, Hanif W, Malik W, et al. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: Results of the VECTOR study. Curr Med Res Opin. 2011;27(7):1367-1374.
- Shete A, Shaikh A, Nayeem KJ, Lily Rodrigues MSSA, Shah P, Khanna R, Majid S, SA Rasheed, Shehla Shaikh TR. Vildagliptin vs sulfonylurea in Indian Muslim diabetes patients fasting during Ramadan. World J Diabetes. 2013;4(6):358.
- Chawla M, Kim TH, Mirasol RC, Faruque P, Hours-zesiger P, Shete A. Initial combination therapy with vildagliptin plus metformin in drug-naïve patients with T2DM: a 24- week real-life study from Asia. Curr Med Res Opin. 2018;34(9):1605-1611.
- Matthews DR, Paldánius PM, Proot P, Chiang Y, Stumvoll M, Prato SD. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year , multicentre , randomised, doubleblind trial. Lancet. 2019;394(10208):1519-1529.
- Matthews D, Del S, Viswanathan P, Mathieu C, Vencio S, Chan JCN. Insights from VERIFY: Early combination therapy provides better glycaemic durability than a stepwise approach in newly diagnosed Type 2 Diabetes. Diabetes Ther. 2020;11(11):2465-2476.